# Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

> **NCT03546192** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 120 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT03546192
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-17
- **Primary completion:** 2015-07-17
- **Final completion:** 2015-07-17
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546192, "Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03546192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*